BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 31] [Cited by in F6Publishing: 43] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Yao M, Cai Y, Wu ZJ, Zhou P, Sai WL, Wang DF, Wang L, Yao DF. Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells. World J Clin Cases 2022; 10(28): 10017-10030 [DOI: 10.12998/wjcc.v10.i28.10017] [Reference Citation Analysis]
2 Zou Z, Sun Y, Wang L, Ma S, Sun C, Zhou Y, Yang G. GIV is a promising novel poor prognostic factor in liver hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e29645. [PMID: 35960100 DOI: 10.1097/MD.0000000000029645] [Reference Citation Analysis]
3 Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Abdom Radiol (NY) 2022;47:596-607. [PMID: 34773467 DOI: 10.1007/s00261-021-03339-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Attia MS, Mohamed AA, El-saady MM, Abou-omar MN, Afify HG, Amin TA, Hosny AH, Youssef AO, Mohy-eldin MS. A new method for early diagnosis of liver cancer using a biosensor embedded in an alginate polymer thin film. J Mater Chem C 2022;10:6464-72. [DOI: 10.1039/d2tc00209d] [Reference Citation Analysis]
5 Lim YS. Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. Korean J Gastroenterol 2021;78:284-8. [PMID: 34824186 DOI: 10.4166/kjg.2021.137] [Reference Citation Analysis]
6 Lin H, Zhang R, Wu W, Lei L. miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A. Oxid Med Cell Longev 2021;2021:9230435. [PMID: 34777698 DOI: 10.1155/2021/9230435] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021;21:1157. [PMID: 34715816 DOI: 10.1186/s12885-021-08904-3] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
8 Chang SD, Cunha GM, Chernyak V. MR Imaging Contrast Agents: Role in Imaging of Chronic Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:329-45. [PMID: 34243921 DOI: 10.1016/j.mric.2021.05.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Ni X, Li D, Dai S, Pan H, Sun H, Ao J, Chen L, Kong H. Development and Evaluation of Nomograms to Predict the Cancer-Specific Mortality and Overall Mortality of Patients with Hepatocellular Carcinoma. Biomed Res Int 2021;2021:1658403. [PMID: 33860031 DOI: 10.1155/2021/1658403] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
10 Cao J, Dong Y, Fan P, Mao F, Chen K, Chen R, Huang B, Cheng Y, Wang WP. Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound. Clin Hemorheol Microcirc 2021. [PMID: 33682701 DOI: 10.3233/CH-201086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
12 Barr RG, Huang P, Luo Y, Xie X, Zheng R, Yan K, Jing X, Luo Y, Xu H, Fei X, Lee JM. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid. Abdom Radiol (NY) 2020;45:3779-88. [PMID: 32424608 DOI: 10.1007/s00261-020-02573-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
13 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chen W, Tang D, Tang D, Dai Y. Epigenetic silencing of ZIC4 contributes to cancer progression in hepatocellular carcinoma. Cell Death Dis 2020;11:906. [PMID: 33097694 DOI: 10.1038/s41419-020-03109-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Li Z, Xiao D, Li X, Zhan P, Wang J, Zhang H. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA. Eur J Gastroenterol Hepatol 2019;31:885-92. [PMID: 30807446 DOI: 10.1097/MEG.0000000000001373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tong AK, Tham WY, Too CW, Tai DW, Chow PK, Ng DC. Molecular Imaging and Therapy of Liver Tumors. Semin Nucl Med 2020;50:419-33. [PMID: 32768006 DOI: 10.1053/j.semnuclmed.2020.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. BMC Gastroenterol 2020;20:215. [PMID: 32646378 DOI: 10.1186/s12876-020-01365-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
18 Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell 2019; 179: 561-577. e22. [PMID: 31585088 DOI: 10.1016/j.cell.2019.08.052] [Cited by in Crossref: 134] [Cited by in F6Publishing: 239] [Article Influence: 67.0] [Reference Citation Analysis]
19 Huang H, Bai Y, Lu X, Xu Y, Zhao H, Sang X. N6-methyladenosine associated prognostic model in hepatocellular carcinoma. Ann Transl Med 2020;8:633. [PMID: 32566570 DOI: 10.21037/atm-20-2894] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
20 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
21 Lu M, Zhang X, Xu Y, He G, Liu Q, Zhu J, Zhang C. Elevated histone H3 citrullination is associated with increased Beclin1 expression in HBV-related hepatocellular carcinoma. J Med Virol 2020;92:1221-30. [PMID: 31900950 DOI: 10.1002/jmv.25663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wu M, Zhou RH, Xu F, Li XP, Zhao P, Yuan R, Lan YP, Zhou WX. Multi-parameter ultrasound based on the logistic regression model in the differential diagnosis of hepatocellular adenoma and focal nodular hyperplasia. World J Gastrointest Oncol 2019; 11(12): 1193-1205 [PMID: 31908724 DOI: 10.4251/wjgo.v11.i12.1193] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Liu H, Zou L, Lu X, Sheng Y, Wang Q, Ding J, Shi L, Liu S, Xing W. Diagnostic Efficacy of Contrast‐Enhanced MRI in Detecting Residual or Recurrent Hepatocellular Carcinoma After Transarterial Chemoembolization: A Systematic Review and Meta‐analysis. J Magn Reson Imaging 2020;52:1019-28. [DOI: 10.1002/jmri.26970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Sun C, Huang S, Wang H, Xie R, Zhang L, Zhou Q, He X, Ju W. Non-SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma. Mol Carcinog 2019;58:2266-75. [PMID: 31523845 DOI: 10.1002/mc.23114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
25 Wang H, Feng LH, Qian YW, Cao ZY, Wu MC, Cong WM. Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior? Ann Transl Med 2019;7:428. [PMID: 31700864 DOI: 10.21037/atm.2019.08.114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
26 Zhang L, Luo B, Dang YW, He RQ, Peng ZG, Chen G, Feng ZB. Clinical Significance of microRNA-196b-5p in Hepatocellular Carcinoma and its Potential Molecular Mechanism. J Cancer 2019;10:5355-70. [PMID: 31632480 DOI: 10.7150/jca.29293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zhou L, Zou M, Zhu K, Ning S, Xia X. Development of 11-DGA-3-O-Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma. Molecules 2019;24:E3080. [PMID: 31450608 DOI: 10.3390/molecules24173080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
28 Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. Hepatology 2019;69:1983-94. [PMID: 30153338 DOI: 10.1002/hep.30233] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 20.3] [Reference Citation Analysis]
29 Wang F, Qi X, Li Z, Jin S, Xie Y, Zhong H. lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3β axis in hepatocellular carcinoma. Cancer Manag Res 2019;11:3813-28. [PMID: 31118799 DOI: 10.2147/CMAR.S197673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
30 Yuan C, Wang Z, Gu D, Tian J, Zhao P, Wei J, Yang X, Hao X, Dong D, He N, Sun Y, Gao W, Feng J. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram. Cancer Imaging. 2019;19:21. [PMID: 31027510 DOI: 10.1186/s40644-019-0207-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
31 Zhai HY, Liang P, Yu J, Cao F, Kuang M, Liu FY, Zhu XY. Comparison of sonazoid and sonoVue in the diagnosis of focal liver lesions: A preliminary study. J Ultrasound Med. 2019;38:2417-2425. [PMID: 30680779 DOI: 10.1002/jum.14940] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
32 Sun L, Dong Z, Gu H, Guo Z, Yu Z. TINAGL1 promotes hepatocellular carcinogenesis through the activation of TGF-β signaling-medicated VEGF expression. Cancer Manag Res 2019;11:767-75. [PMID: 30697069 DOI: 10.2147/CMAR.S190390] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
33 Zhao J, Wu C, Zhai L, Shi X, Li X, Weng G, Zhu J, Li J, Zhao J. A SERS-based immunoassay for the detection of α-fetoprotein using AuNS@Ag@SiO 2 core–shell nanostars. J Mater Chem C 2019;7:8432-41. [DOI: 10.1039/c9tc01890e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
34 Zheng BH, Liu LZ, Zhang ZZ, Shi JY, Dong LQ, Tian LY, Ding ZB, Ji Y, Rao SX, Zhou J, Fan J, Wang XY, Gao Q. Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer. 2018;18:1148. [PMID: 30463529 DOI: 10.1186/s12885-018-5024-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 69] [Article Influence: 13.0] [Reference Citation Analysis]
35 Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M, Liu LZ, Shi JY, Yang LX, Wang ZC, Zhang S, Ding ZB, Ke AW, Cao Y, Zhang XM, Zhou J, Fan J, Wang XY, Gao Q. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics 2018;8:5690-702. [PMID: 30555574 DOI: 10.7150/thno.28742] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
36 Li Q, Wang W, Hu YC, Yin TT, He J. Knockdown of Ubiquitin Associated Protein 2-Like (UBAP2L) Inhibits Growth and Metastasis of Hepatocellular Carcinoma. Med Sci Monit. 2018;24:7109-7118. [PMID: 30291221 DOI: 10.12659/msm.912861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
37 Joo I, Lee JM, Lee DH, Jeon JH, Han JK. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 2019;29:1724-32. [PMID: 30255250 DOI: 10.1007/s00330-018-5727-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]
38 Wang Y, Sun L, Wang L, Liu Z, Li Q, Yao B, Wang C, Chen T, Tu K, Liu Q. Long non-coding RNA DSCR8 acts as a molecular sponge for miR-485-5p to activate Wnt/β-catenin signal pathway in hepatocellular carcinoma. Cell Death Dis 2018;9:851. [PMID: 30154476 DOI: 10.1038/s41419-018-0937-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 89] [Article Influence: 16.0] [Reference Citation Analysis]
39 Miao Y, Zhang Y, Yin L. Trends in hepatocellular carcinoma research from 2008 to 2017: a bibliometric analysis. PeerJ 2018;6:e5477. [PMID: 30128213 DOI: 10.7717/peerj.5477] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
40 Lin JZ, Bai Y, Wang AQ, Long JY, Xu WY, Hu K, Zhao L, Pan J, Sang XT, Zhao HT. Multidisciplinary management of hepatobiliary tumors in the era of precision medicine. Hepatobiliary Pancreat Dis Int 2018;17:381-2. [PMID: 30082196 DOI: 10.1016/j.hbpd.2018.07.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Finn RS. Searching for common ground in a global disease. Hepatobiliary Surg Nutr 2018;7:297-9. [PMID: 30221159 DOI: 10.21037/hbsn.2018.04.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 56] [Article Influence: 16.3] [Reference Citation Analysis]
43 Zhong C, Zhang YF, Huang JH, Xiong CM, Wang ZY, Chen QL, Guo RP. Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study. BMC Cancer 2018;18:643. [PMID: 29879928 DOI: 10.1186/s12885-018-4557-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Foerster F, Galle PR. Hepatocellular carcinoma: one world, one cancer-different guidelines? Hepatobiliary Surg Nutr 2018;7:41-3. [PMID: 29532810 DOI: 10.21037/hbsn.2018.01.05] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]